Utama › Limfoma Sel Mantel
Kajian klinikal Limfoma Sel Mantel sedang mengambil peserta di AS
70 kajian untuk Limfoma Sel Mantel sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Baldwin Park, CA15 kajian
- Houston, TX15 kajian
- Durham, NC13 kajian
- Milwaukee, WI12 kajian
- Seattle, WA12 kajian
- New York City, NY12 kajian
- Boston, MA11 kajian
- Columbus, OH11 kajian
- Nashville, TN11 kajian
- Chicago, IL10 kajian
- Portland, OR9 kajian
- Rochester, MN9 kajian
- St. Louis, MO8 kajian
- Atlanta, GA8 kajian
- Denver, CO8 kajian
- Mountain View, CA7 kajian
- Cleveland, OH7 kajian
- Los Angeles, CA7 kajian
- Dallas, TX6 kajian
- Salt Lake City, UT6 kajian
- Miami, FL6 kajian
- Jacksonville, FL6 kajian
- Ann Arbor, MI6 kajian
- Buffalo, NY5 kajian
- Kansas City, MO5 kajian
- Charlotte, NC5 kajian
- Tampa, FL5 kajian
- Baltimore, MD5 kajian
- New Haven, CT5 kajian
- Washington, DC5 kajian
- Philadelphia, PA5 kajian
- San Diego, CA5 kajian
- Edison, NJ5 kajian
- Providence, RI4 kajian
- Minneapolis, MN4 kajian
- Pittsburgh, PA4 kajian
- Charlottesville, VA4 kajian
- Richmond, VA4 kajian
- Queens, NY4 kajian
- Omaha, NE4 kajian
Mengikut negeri
- Alabama4 kajian
- Arizona6 kajian
- California29 kajian
- Colorado10 kajian
- Connecticut6 kajian
- Delaware3 kajian
- Florida16 kajian
- Georgia9 kajian
- Illinois10 kajian
- Indiana4 kajian
- Iowa5 kajian
- Kansas7 kajian
- Kentucky4 kajian
- Louisiana3 kajian
- Maryland9 kajian
- Massachusetts13 kajian
- Michigan8 kajian
- Minnesota14 kajian
- Missouri8 kajian
- Nebraska4 kajian
- New Jersey8 kajian
- New York16 kajian
- North Carolina17 kajian
- Ohio16 kajian
- Oregon9 kajian
- Pennsylvania9 kajian
- Rhode Island4 kajian
- Tennessee12 kajian
- Texas19 kajian
- Utah6 kajian
- Virginia7 kajian
- Washington14 kajian
- Wisconsin13 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Mengambil pesertaFasa 3
Umur 60 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05976763Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 110 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05724121Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07763210Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06252675A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06542250The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07285044A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06697184Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06553872Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06784167A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06029309Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07003295Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06564038A Study of ARC-02 in B-cell NHL
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT07691606Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT07673367AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Mengambil pesertaFasa 1
Umur 18 hingga 85 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT05887167Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Mengambil pesertaFasa 1
Umur 18 hingga 81 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT05990465Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06675123A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT07121946Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.